We recently published a list of 12 Most Expensive Stocks Insiders Are Buying After Trump’s Tariff Rollout. In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other most expensive stocks insiders are buying after Trump’s tariff rollout.
Wall Street banks have sharply cut their targets for the broader market index due to growing fears about the economic fallout from new tariffs, writes the Financial Times. Since the tariff announcement on April 2, the broader market index has dropped nearly 7%. Major banks now expect lower market gains in 2025, with some analysts predicting a possible bear market directly triggered by presidential policy shifts.
Amid tariff wars and market uncertainty, insider trading often draws attention. Insider stock purchases may signal executive confidence, while sales aren’t necessarily negative—they could reflect personal or diversification choices. It’s best to view insider trading in context with a company’s financials and market conditions.
Our Methodology
Today, we’re highlighting most expensive stocks that insiders have been buying in April. Using Insider Monkey’s trading screener, we looked for companies with share prices of at least $30 and insider purchases between April 2 and April 21. From there, we ranked the top 12 stocks based on the highest average purchase price per share.
Stocks that were recently covered were excluded from this list. Most of those can be seen on this list of the 19 mid- and large-cap stocks insiders are buying after Trump’s tariff rollout.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A medical professional in scrubs providing care to a patient.
Nutex Health Inc. (NASDAQ:NUTX)
Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services and operations company based in Houston, Texas. It operates through three segments: Hospital, Population Health Management, and Real Estate, offering services like 24/7 emergency and inpatient care, imaging, labs, and pharmacy support. The company also manages physician groups, runs a cloud-based healthcare platform, and owns hospital properties across the U.S.
On April 8, the company’s CFO Christian Jon Bates purchased around $81,810 worth of Nutex Health shares at an average price of $81.81 per share. Year-to-date, the stock gained 370.18% and is now trading at $149 per share. Over the past 12 months, Nutex Health returned 2,962.55% to its investors.
For the year ended December 31, 2024, Nutex Health (NASDAQ:NUTX) reported total revenue of $479.9 million, up 93.8% from 2023, driven largely by $169.7 million in arbitration-related revenue. The company achieved $130.6 million in operating income, a major turnaround from a $31.8 million loss the previous year, and posted net income of $52.2 million. Adjusted EBITDA soared to $123.7 million, up over 1,000% year-over-year, with hospital visits rising nearly 17% to 168,388.
Nutex Health (NASDAQ:NUTX) is also one of the 12 best performing small cap stocks so far in 2025.
Overall, NUTX ranks 3rd on our list of most expensive stocks insiders are buying after Trump’s tariff rollout. While we acknowledge the potential of NUTX, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUTX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
